Stellantis Backs Out of Hydrogen Venture With Michelin, Forvia
The maker of Fiat cars plans to stop investing in the Symbio business that specializes in hydrogen fuel cells by 2026, Forvia and Michelin said in separate statements in response to Bloomberg queries. Stellantis didn't immediately respond to a request for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Aptiv forecasts better-than-expected 2025 profit despite auto tariffs hit
(Reuters) -Aptiv PLC forecast a bigger-than-expected annual adjusted profit on Thursday, banking on resilient demand for its auto parts despite pressure from U.S. tariffs and higher costs. U.S.-listed shares of the Dublin-based company rose nearly 3% in premarket trade. Strong demand from automakers for advanced driver-assistance features and infotainment systems has helped companies like Aptiv. But U.S. President Donald Trump's tariffs have hit the import-heavy automotive industry. Global demand for electric vehicles has also slowed down, forcing Aptiv to cut costs last year. Aptiv, which sources components globally for its auto parts business, counts major automakers such as the Detroit Three, Volkswagen AG and BMW among its key clients. The supplier now expects annual adjusted earnings per share between $7.30 and $7.60, above analysts' estimates of $7.23, according to data compiled by LSEG. On an adjusted basis, Aptiv earned $2.12 per share in the quarter through June, compared with estimates of $1.84 per share. Overall quarterly net sales rose 3% to $5.2 billion from a year ago. Analysts on average expected net sales of $5.09 billion.
Yahoo
14 minutes ago
- Yahoo
Revealed – How Much Inter Milan Cash In After Sevilla Buy 40% Of France U21 Star's Rights
Inter Milan have brought in €4 million after Sevilla bought 40% of the playing rights of midfielder Lucien Agoume. This according to today's print edition of Rome-based newspaper Corriere dello Sport, via FCInterNews. Inter Milan sold midfielder Lucien Agoume to Sevilla last summer. The La Liga club paid a fee of just €4 million to take the midfielder off of Inter's hands. There was a catch, however. The Nerazzurri retained 50% of Agoume's playing rights as part of the deal. Therefore, Inter were entitled to a sell-on fee equal to half of any transfer fee that Sevilla are to receive for Agoume in the future. Inter Cash In €4M As Sevilla Activate Lucien Agoume Clause BELGRADE, SERBIA – APRIL 01: Lucien Agoume of France reacts during the Elite Round Group B match between France U17 and Slovakia U17 at Stadium Zemun on April 1, 2019 in Belgrade, Serbia. (Photo by) However, Sevilla had the option to buy an additional 40% of Agoume's playing rights. This would take the Andalusian club's total ownership of the Frenchman's rights to 90%. Therefore, the sell-on fee that Inter would receive for Agoume would be 10% rather than 50%. Therefore, the Corriere dello Sport report, Inter have received a fee of €4 million from the Spaniards, and have relinquished all but 10% of the midfielder's playing rights.
Yahoo
14 minutes ago
- Yahoo
AbbVie lifts annual profit forecast on strong demand for newer immunology drugs
(Reuters) -AbbVie raised its 2025 profit forecast on Thursday, after beating Wall Street estimates for second-quarter results on strong sales of its newer immunology drugs Skyrizi and Rinvoq. The company is pushing Skyrizi and Rinvoq to counter the drop in sales of Humira, as the once-bestselling drug faces competition from several cheaper biosimilars that began hitting the U.S. market in 2023. "We're entering the second half of the year with substantial momentum," said CEO Robert Michael. Skyrizi recorded quarterly sales of $4.42 billion, beating analysts' average estimate of $4 billion, while Rinvoq sales of $2.03 billion surpassed estimates of $1.97 billion, according to data compiled by LSEG. The North Chicago-based drugmaker has spent more than $20 billion on acquisitions since 2023 as Humira lost patent protection. On Wednesday, Bloomberg News reported that AbbVie is in talks to acquire privately held psychiatric disorder drug developer Gilgamesh Pharmaceuticals in a deal worth about $1 billion. Global sales of arthritis treatment Humira, once the world's best-selling drug, came in at $1.18 billion in the second quarter, missing estimates of $1.45 billion. AbbVie's forecast raise comes on the back of the European Union's framework trade deal with the United States, under which all EU-produced pharmaceuticals entering the U.S. will be subject to a 15% tariff. AbbVie has a significant manufacturing presence in Ireland, where it makes its wrinkle treatment Botox. The company now expects adjusted annual profit per share between $11.88 and $12.08, compared with its previous expectations of $11.67 to $11.87. The company earned quarterly adjusted profit per share of $2.97, compared with estimates of $2.88.
